This contention is supported by findings that administration of ipilimumab or PD-1-targeted MAbs to patients with advanced melanoma is accompanied by rapid diversification of the T cell repertoire (102–104), described by the authors of one of these studies as being “both detrimental and beneficial for patients with cancer” (102). This evidence concerns the gene PDCD1 and melanoma.